| Antibodies and antibody fragments against HNAV1. 7 channel and their use in pain and cancer indications M Martina, B Chakravarthy, Y Durocher, M Arbabi-Ghahroudi, A Marcil, ... US Patent 11,945,858, 2024 | | 2024 |
| Tgf-b-receptor ectodomain fusion molecules and uses thereof AEG Lenferink, JC Zwaagstra, T Sulea, MD O'Connor-McCourt US Patent App. 18/457,588, 2024 | | 2024 |
| Progress and challenges in computational structure-based design and development of biologic drugs T Sulea, S Kumar, D Kuroda Frontiers in Molecular Biosciences 11, 1360267, 2024 | | 2024 |
| TGF-β-receptor ectodomain fusion molecules and uses thereof AEG Lenferink, JC Zwaagstra, T Sulea, MD O'Connor-McCourt US Patent 11,866,481, 2024 | | 2024 |
| A glyco-engineering approach for site-specific conjugation to Fab glycans ML Jaramillo, T Sulea, Y Durocher, M Acchione, MJ Schur, A Robotham, ... MAbs 15 (1), 2149057, 2023 | 6 | 2023 |
| Effects of Two Soluble ACE2-Fc Variants on Blood Pressure and Albuminuria in Hypertensive Mice M Trentin-Sonoda, J Zimpelmann, K Tailor, JW Gillard, N Yoganathan, ... Canadian Journal of Kidney Health and Disease 10, 20543581231207146, 2023 | | 2023 |
| Enhanced antibody-antigen structure prediction from molecular docking using AlphaFold2 F Gaudreault, CR Corbeil, T Sulea Scientific Reports 13 (1), 15107, 2023 | 3 | 2023 |
| Comparative Performance of High-Throughput Methods for Protein pKa Predictions W Wei, H Hogues, T Sulea Journal of Chemical Information and Modeling 63 (16), 5169-5181, 2023 | 2 | 2023 |
| Solvated interaction energy: from small-molecule to antibody drug design EO Purisima, CR Corbeil, F Gaudreault, W Wei, C Deprez, T Sulea Frontiers in Molecular Biosciences 10, 1210576, 2023 | 1 | 2023 |
| Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM … J Metcalf, A Nielsen, S Prabhu, N Robinson, S Marinacci, N Grinshtein, ... Cancer Research 83 (8_Supplement), LB313-LB313, 2023 | | 2023 |
| Antibody glycoconjugates and methods of production and use M Gilbert, T Sulea, ML Jaramillo, Y Durocher, M Acchione US Patent 11,591,408, 2023 | | 2023 |
| Exploring rigid-backbone protein docking in biologics discovery: a test using the DARPin scaffold F Gaudreault, J Baardsnes, Y Martynova, A Dachon, H Hogues, ... Frontiers in Molecular Biosciences 10, 2023 | | 2023 |
| Optimizing Antibody–Antigen Binding Affinities with the ADAPT Platform T Sulea, C Deprez, CR Corbeil, EO Purisima Computer-Aided Antibody Design, 361-374, 2022 | 2 | 2022 |
| Antigen-binding agents that specifically bind epidermal growth factor receptor variant iii S McComb, RD Weeratna, M Jaramillo, A Marcil, T Sulea, WU Cunle, ... US Patent App. 17/441,706, 2022 | | 2022 |
| Antibody mutations favoring pH‐dependent binding in solid tumor microenvironments: Insights from large‐scale structure‐based calculations W Wei, CR Corbeil, F Gaudreault, C Deprez, EO Purisima, T Sulea Proteins: Structure, Function, and Bioinformatics 90 (8), 1538-1546, 2022 | 4 | 2022 |
| Programmable attenuation of antigenic sensitivity for a nanobody-based EGFR chimeric antigen receptor through hinge domain truncation S McComb, T Nguyen, A Shepherd, KA Henry, D Bloemberg, A Marcil, ... Frontiers in Immunology 13, 864868, 2022 | 9 | 2022 |
| Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor A Yogi, G Hussack, H van Faassen, AS Haqqani, CE Delaney, E Brunette, ... Pharmaceutics 14 (7), 1452, 2022 | 18 | 2022 |
| Serum albumin binding antibodies for tuneable half-life extension of biologics G Hussack, J Tanha, K Henry, T Sulea US Patent 11,384,141, 2022 | | 2022 |
| Anti-egfrviii antibodies and antigen-binding fragments thereof A Marcil, M Jaramillo, T Sulea, M Moreno, WU Cunle US Patent App. 17/441,708, 2022 | | 2022 |
| Humanized anti-S100A9 antibody and uses thereof P Tessier, M Tardif, T Sulea US Patent 11,359,010, 2022 | | 2022 |
Tudor OpreaCEO, Expert Systems Inc在 expertsystems.inc 的电子邮件经过验证
